G
GeneMatters
GeneMatters is a genetic counseling service
About GeneMatters
GeneMatters is a company that specializes in providing expert genetic counseling services to patients across the United States and Canada. The company operates in the healthcare sector, focusing on genetic counseling, which involves helping individuals interpret their genetic family history, decide if genetic testing is appropriate, choose the right test, and understand the results to make informed medical decisions. GeneMatters serves a diverse range of clients, including healthcare organizations that require additional genetic counseling support to serve their patient appointments. The company employs board-certified and licensed genetic counselors who have degrees from programs recognized by the Accreditation Council for Genetic Counseling and are continually trained in the rapidly advancing field of genetics. GeneMatters' business model revolves around offering remote genetic counseling services, ensuring accessibility and convenience for patients without the need for travel or long wait times. The company generates revenue by partnering with healthcare organizations and providing genetic counseling services on a contractual basis. GeneMatters' market includes healthcare providers, hospitals, and clinics that need specialized genetic counseling expertise to enhance their patient care services. Keywords: genetic counseling, healthcare, remote services, patient care, genetic testing, board-certified, U.S., Canada, medical specialties, healthcare organizations.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2016
- Headquarters
- Minneapolis, United States
- Employees
- 9
- Open positions
- None listed
- Dealroom signal
- 65.5/100
- Industry
- Health
- Sub-industry
- Health Platform
- Sector
- Health Tech & Medtech, Testing, Risk Management, Oncology, Hard Tech, medical testing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning GeneMatters.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Aug 2021 | $0 | — | Genome Medical | — |
| EARLY VCOther financing | Jul 2020 | $10M | $41M | Undisclosed | — |
Growth signals
Latest recorded traffic for GeneMatters is 2.7K monthly website visits, up 390.9% over the last three months. GeneMatters's team declined 66.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Other known investors3 additional known investors
Genome Medical
Argonautic Ventures
iSelect Fund
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about GeneMatters on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See GeneMatters’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.